Cargando…

Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins

Multiple myeloma is a neoplastic disease of plasma cells that produces monoclonal immunoglobulins, known as monoclonal proteins, causing hypercalcemia, anemia, renal insufficiency, bone lesion, and other organ damage. In most multiple myeloma, the amount of monoclonal protein correlates with the tum...

Descripción completa

Detalles Bibliográficos
Autor principal: Soma, Shunsuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246476/
https://www.ncbi.nlm.nih.gov/pubmed/35800800
http://dx.doi.org/10.7759/cureus.25513
_version_ 1784738981161730048
author Soma, Shunsuke
author_facet Soma, Shunsuke
author_sort Soma, Shunsuke
collection PubMed
description Multiple myeloma is a neoplastic disease of plasma cells that produces monoclonal immunoglobulins, known as monoclonal proteins, causing hypercalcemia, anemia, renal insufficiency, bone lesion, and other organ damage. In most multiple myeloma, the amount of monoclonal protein correlates with the tumor burden and reflects its prognosis. Uninvolved immunoglobulins are often suppressed as monoclonal protein levels increase as a result of the increasing percentage of myeloma cells in the bone marrow. Detection of monoclonal protein by protein electrophoresis, immunofixation, and serum-free light chain assay is a highly sensitive analysis and is not suitable as a screening test because it is positive in a few percent of healthy elderly people, the majority of whom are classified as benign monoclonal gammopathy of undetermined significance. Therefore, it is widely used in practice to measure quantitation of immunoglobulins by nephelometer, and only when uninvolved immunoglobulins are decreasing in the values for each subtype, monoclonal protein identification by immunofixation, serum-free light chain assay, and bone marrow examination must be additionally performed for proactively diagnosing multiple myeloma. However, we experienced symptomatic multiple myeloma in which uninvolved immunoglobulins were not suppressed and there were no significant changes in immunoglobulin levels despite the relatively rapid progression. It would suggest that if you suspect symptomatic myeloma, you should not rule out the possibility of multiple myeloma because of preserved uninvolved immunoglobulins in laboratory findings.
format Online
Article
Text
id pubmed-9246476
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-92464762022-07-06 Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins Soma, Shunsuke Cureus Family/General Practice Multiple myeloma is a neoplastic disease of plasma cells that produces monoclonal immunoglobulins, known as monoclonal proteins, causing hypercalcemia, anemia, renal insufficiency, bone lesion, and other organ damage. In most multiple myeloma, the amount of monoclonal protein correlates with the tumor burden and reflects its prognosis. Uninvolved immunoglobulins are often suppressed as monoclonal protein levels increase as a result of the increasing percentage of myeloma cells in the bone marrow. Detection of monoclonal protein by protein electrophoresis, immunofixation, and serum-free light chain assay is a highly sensitive analysis and is not suitable as a screening test because it is positive in a few percent of healthy elderly people, the majority of whom are classified as benign monoclonal gammopathy of undetermined significance. Therefore, it is widely used in practice to measure quantitation of immunoglobulins by nephelometer, and only when uninvolved immunoglobulins are decreasing in the values for each subtype, monoclonal protein identification by immunofixation, serum-free light chain assay, and bone marrow examination must be additionally performed for proactively diagnosing multiple myeloma. However, we experienced symptomatic multiple myeloma in which uninvolved immunoglobulins were not suppressed and there were no significant changes in immunoglobulin levels despite the relatively rapid progression. It would suggest that if you suspect symptomatic myeloma, you should not rule out the possibility of multiple myeloma because of preserved uninvolved immunoglobulins in laboratory findings. Cureus 2022-05-31 /pmc/articles/PMC9246476/ /pubmed/35800800 http://dx.doi.org/10.7759/cureus.25513 Text en Copyright © 2022, Soma et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Soma, Shunsuke
Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title_full Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title_fullStr Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title_full_unstemmed Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title_short Multiple Myeloma With a Rare Presentation at Preserved Uninvolved Immunoglobulins
title_sort multiple myeloma with a rare presentation at preserved uninvolved immunoglobulins
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246476/
https://www.ncbi.nlm.nih.gov/pubmed/35800800
http://dx.doi.org/10.7759/cureus.25513
work_keys_str_mv AT somashunsuke multiplemyelomawithararepresentationatpreserveduninvolvedimmunoglobulins